HIGHLIGHTS
- who: Matteo Allegretti et al. from the Ohio State University, United States have published the paper: Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report, in the Journal: (JOURNAL)
SUMMARY
Hormone-receptor (HR) positive breast cancer includes the luminal A and luminal B subtypes and is the most common type of tumor in women diagnosed with early-stage breast cancer. Trastuzumab Deruxtecan (T-DXd), recently approved for HER2+ advanced tumors, is expected to have a strong clinical impact on HR+/HER2-low luminal breast . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.